Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Rizatriptan Benzoate Tablets

Rizatriptan benzoate tablets are analgesics used for the acute treatment of migraine attacks with or without aura.

Only used to treat confirmed migraine.

This product is contraindicated for ischemic heart disease and uncontrolled hypertension, and is contraindicated for patients with hemiplegic or brainstem aura migraine… Details 
Comprehensive interpretation of Rizatriptan benzoate tablets


Effects:
For the acute treatment of migraine attacks with or without aura. Note: Rizatriptan benzoate is only suitable for confirmed migraine, not for the prevention of migraine, nor for patients with hemiplegic or basilar migraine.

Usage and dosage:
The recommended dose for adults with acute migraine attacks is 10mg or 5mg. Recommended dose for first use: 10mg (2 tablets) Adult re-dosing dose: If migraine attacks again, the drug can be used again 2 hours after the first dose, and the dose should not exceed 30mg within 24 hours. The safety of the drug for patients with an average of more than 4 headaches every 30 days has not been confirmed. The dosage for children aged 6-17 years should be adjusted according to the child’s weight. Recommended dose: 5 mg for those with a weight of less than 40 kg and 10 mg for those with a weight of ≥40 kg. Dose adjustment for patients using propranolol Adults: For adult patients who are also using propranolol, the recommended dose of this product is 5 mg, and the medication should not exceed 3 times within 24 hours (i.e. 15 mg). Children: For children with a weight of ≥40 kg who are also using propranolol: The recommended dose of this product is 5 mg (the maximum dose within 24 hours is 5 mg). This product is not recommended for children with a weight of less than 40 kg who are also using propranolol.

Adverse reactions:
This product is well tolerated, with mild and short-lived adverse reactions. The main adverse events are weakness, fatigue, drowsiness, pain or pressure, and dizziness. Serious cardiac accidents, including death after the use of 5-HT1 agonists,

Share:

Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.